Is Thrombocytopenia Getting in the Way of Your Procedures?^*

*Please see study design and exclusion criteria on the Efficacy page.

In clinical trials

The Majority of Patients Treated With Mulpleta Achieved a Platelet Count of ≥50,000/μL and Had a Minimum Increase of 20,000/µL From Baseline

Please see study design and exclusion criteria on the Efficacy page.

Mulpleta is a thrombopoietin receptor agonist for the treatment of thrombocytopenia in
adult patients with chronic liver disease who are scheduled to undergo a procedure.

Efficacy

The majority of patients
achieved a platelet count ≥50,000/µL

View Results

Safety

Safety profile similar
to placebo

Review Safety

Dosing

One 3-mg tablet taken
once daily with or
without food for 7 days

Learn about dosing

Access

Mulpleta is easy
to access

Get Started

Warnings and Precautions

Mulpleta is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Portal vein thrombosis was reported in 1% of Mulpleta-treated patients and 1% of placebo-treated patients.

Consider the potential increased thrombotic risk when administering Mulpleta to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency). Monitor platelet counts and for thromboembolic events and institute treatment promptly.

Mulpleta should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Is Thrombocytopenia Getting in the Way of Your Procedures?^*

In clinical trials

The Majority of Patients Treated With Mulpleta Achieved a Platelet Count of ≥50,000/μL and Had a Minimum Increase of 20,000/µL From Baseline

Efficacy

Safety

Dosing

Access

Indication

Important Safety Information

Warnings and Precautions

Adverse Reactions

Is Thrombocytopenia Getting in the Way of Your Procedures?*

In clinical trials

The Majority of Patients Treated With Mulpleta Achieved a Platelet Count of ≥50,000/μL and Had a Minimum Increase of 20,000/µL From Baseline

Efficacy

Safety

Dosing

Access

Indication

Important Safety Information

Warnings and Precautions

Adverse Reactions

Is Thrombocytopenia Getting in the Way of Your Procedures?^*